페이지 정보관리자 | 20-12-01 09:21 | 203 Views
Daewoong Pharmaceutical’s Olostar proved its excellent blood pressure reduction effects, Published in an SCI-grade journal
- Published in the American Journal of Therapeutics
- Proved its excellent blood pressure reduction effects and blood lipid concentration improvements compared to other ARBs and statins
- Confirmed its high drug compliance of fixed-dose combination compared to single-pill combination
Clinical research of Olostar, a treatment for hypertension and dyslipidemia by Daewoong Pharmaceutical, has gained international approval.
Daewoong Pharmaceutical (Daewoong) (CEO Sengho Jeon) has revealed on the 11th that research on the excellent blood pressure reduction effects of Olostar, a combination tablet of olmesartan with rosuvastatin, has been published in the American Journal of Therapeutics, an SCI-grade international journal.
This published research targeted 112 patients of acute coronary syndrome (ACS) over 18 with hypertension, and randomly divided the participants into two groups; one group with 55 people was administered Olostar, and the other group with 57 people was administered a combination of atorvastatin and angiotensin II receptor blockers (ARBs) excluding olmesartan. And by close monitoring the subjects’ blood pressure and cholesterol control after administration for 12 months, the effect between two groups were compared.
The results of the research indicated a meaningful decrease in both systolic and diastolic blood pressure on group with Olostar relative to the other group that was administered a combination of other ARBs and atorvastatin. It also displayed improvement on blood lipids concentration, such as a drastic decrease in low-density lipoprotein cholesterol (LDL-C) and more.
In addition, from the research, fixed-dose combination (FDC) has been confirmed to have higher drug compliance than single-pill combination (SPC). During the 12-month close monitoring period, only 5 FDC subjects stopped the treatment with Olostar, while 20 SPC subjects stopped the treatment with other ARBs and atorvastatin. Antihypertensives and statins are already known for their efficacy on reducing the reoccurrence of cardiovascular diseases in patients who have experienced it in the past. Therefore, the drug compliance is important for preventing the reoccurrence of cardiovascular diseases in ACS patients.
Jinman Cho, Director of Kyung Hee University Hospital at Gangdong’s Cardiovascular Center, who proceeded this clinical study, said, “Olmesartan has a longer half-life and better blood pressure regulation than other ARBs, and rosuvastatin shows excellent LDL-C reducing effects with low doses, so I proceeded this research with the hypothesis that a combination of the two will bring superior effects compared to other drugs.”
“Since FDC has a higher drug compliance than SPC, patients took the medication well, and it was confirmed that the drug is effective in controlling blood pressure and cholesterol as a result,” he added.
Changjae Lee, Vice President of Daewoong’s Sales & Marketing Division, said, “As Olostar’s clinical research results are published on a globally recognized journal, the value of Olostar has been recognized even more.” “We will do our best to contribute to better quality of life for many patients with both hypertension and dyslipidemia through continuous R&D after Olostar and Olomax, both of which are already released.”
On the other hand, Olostar is an incrementally modified drug developed with Daewoong’s technology. Its distinctive feature is the optimized drug absorption into the body using Daewoong’s patented platform technology, the release rate controlling bi-layered tablet formulation. For its excellence in technology, Daewoong was awarded the technology award in the 16th Korea New Drug Development Award in 2015, and was listed in the 2020 National R&D Excellence Top 100.
# # #